Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial
NCT04069312Phase 3Completed
- Sponsor
- Johns Hopkins University
- Start
- Feb 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roflumilast, azithromycin in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), sponsored by Johns Hopkins University. Started Feb 2020; status: completed.
02
Drugs
roflumilastazithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT04069312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069312.